CancerDrs

Head and Neck Cancer clinical trials in Minnesota

33 actively recruiting head and neck cancer trials at 48 sites across Minnesota.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin

This phase III trial compares cetuximab to chemotherapy, carboplatin and paclitaxel, with intensity modulated radiation therapy for the treatment of patients with head and neck cancer that may have spread from where it first started to nea…

Sponsor: NRG Oncology
NCT ID: NCT07441681
Sites in Minnesota:
  • Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

The goal of this study is to understand whether CRB-701, a targeted form of chemotherapy called an anti-body drug conjugate, will work as a treatment for oropharyngeal (throat, tonsil) cancer. In patients who have already received platinum…

Sponsor: Corbus Pharmaceuticals Inc.
NCT ID: NCT07768189
Sites in Minnesota:
  • Mayo Clinic in Rochester — Rochester, Minnesota
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junct…

Sponsor: SOFIE
NCT ID: NCT07217704
Sites in Minnesota:
  • Mayo Clinic Rochester — Rochester, Minnesota
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors

This phase III trial studies how well pafolacianine works for identifying cancerous lesions in children and adolescent patients with primary solid tumors or solid tumors that have spread from where they first started (primary site) to othe…

Sponsor: Mayo Clinic
NCT ID: NCT06915727
Sites in Minnesota:
  • Mayo Clinic in Rochester — Rochester, Minnesota
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Minnesota:
  • Riverwood Healthcare Center — Aitkin, Minnesota
  • Mayo Clinic Health System in Albert Lea — Albert Lea, Minnesota
  • Essentia Health - Baxter Clinic — Baxter, Minnesota
  • Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
  • Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Minnesota:
  • Local Institution - 2132 — Saint Paul, Minnesota
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combinatio…

Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT04198766
Sites in Minnesota:
  • HealthPartners Cancer Research Center — Saint Louis Park, Minnesota
  • HealthPartners Cancer Research Center (Regions Hospital) — Saint Paul, Minnesota
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…

Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Minnesota:
  • M Health Fairview University of Minnesota Medical Center — Minneapolis, Minnesota
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…

Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in Minnesota:
  • Mayo Rochester — Rochester, Minnesota
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carc…

Sponsor: Daiichi Sankyo
NCT ID: NCT06172478
Sites in Minnesota:
  • Health Partners Frauenshuh Cancer Center — Saint Louis Park, Minnesota
  • Health Partners Cancer Center at Regions Hospital — Saint Paul, Minnesota
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC)…

Sponsor: A2 Biotherapeutics Inc.
NCT ID: NCT06682793
Sites in Minnesota:
  • Mayo Clinic — Rochester, Minnesota
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia

This is a Phase IIa oral cavity leukoplakia study of pioglitazone 15mg and metformin 500mg BID for 12 weeks. The primary objective is to determine the clinical and histologic changes of leukoplakia from baseline following a 12 week course …

Sponsor: University of Minnesota
NCT ID: NCT05727761
Sites in Minnesota:
  • University of Minnesota — Minneapolis, Minnesota
  • HealthPartners — Saint Paul, Minnesota
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial

This phase II trial compares the effect of adding proton spatially fractionated radiotherapy (SFRT) or photon stereotactic body radiotherapy (SBRT) to standard immunotherapy pembrolizumab before surgery (neoadjuvant) in treating patients w…

Sponsor: Mayo Clinic
NCT ID: NCT07783581
Sites in Minnesota:
  • Mayo Clinic in Rochester — Rochester, Minnesota
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Minnesota:
  • Allina Health Cancer Institute - Mercy Hospital — Coon Rapids, Minnesota
  • Allina Health Cancer Institute - Abbott Northwestern Hospital — Minneapolis, Minnesota
  • Allina Health Cancer Institute - United Hospital — Saint Paul, Minnesota
  • Allina Health Cancer Institute — Saint Paul, Minnesota
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Minnesota:
  • Exelixis Clinical Site #68 — Rochester, Minnesota
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-d…

Sponsor: IDEAYA Biosciences
NCT ID: NCT07277413
Sites in Minnesota:
  • Mayo Clinic Rochester — Rochester, Minnesota
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Ce…

Sponsor: AbbVie
NCT ID: NCT05005403
Sites in Minnesota:
  • M Health Fairview University of Minnesota Medical Center - East Bank /ID# 276200 — Minneapolis, Minnesota
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion stu…

Sponsor: SparX Biotech(Jiangsu) Co., Ltd.
NCT ID: NCT06259552
Sites in Minnesota:
  • Mayo Clinic Rochester — Rochester, Minnesota
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Minnesota:
  • Riverwood Healthcare Center — Aitkin, Minnesota
  • Mayo Clinic Health System in Albert Lea — Albert Lea, Minnesota
  • Essentia Health - Baxter Clinic — Baxter, Minnesota
  • Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
  • Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

This clinical trial is being done to learn whether using the proactive, graduated dose modification algorithm for leucovorin, 5-fluorouracil (5-FU), and oxaliplatin (FOLFOX) (PAGODA) algorithm to guide chemotherapy dosing for the FOLFOX re…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in Minnesota:
  • Riverwood Healthcare Center — Aitkin, Minnesota
  • Essentia Health - Baxter Clinic — Baxter, Minnesota
  • Sanford Joe Lueken Cancer Center — Bemidji, Minnesota
  • Essentia Health Saint Joseph's Medical Center — Brainerd, Minnesota
  • Minnesota Oncology - Burnsville — Burnsville, Minnesota
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Minnesota:
  • Massive Bio SYNERGY-AI site — Duluth, Minnesota
View on ClinicalTrials.gov →
Recruiting Academic/Other

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…

Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Minnesota:
  • Riverwood Healthcare Center — Aitkin, Minnesota
  • Essentia Health-St. Joseph's Medical Center — Brainerd, Minnesota
  • Essentia Health - Duluth Clinic — Duluth, Minnesota
  • St. Luke's Hospital of Duluth — Duluth, Minnesota
  • Lake Region Healthcare — Fergus Falls, Minnesota
View on ClinicalTrials.gov →

Showing 25 of 33 trials with sites in Minnesota. See all head and neck cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-11-09